Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement
James C. Moon,Daniel Messroghli,Peter Kellman,Stefan K. Piechnik,Matthew D. Robson,Martin Ugander,Peter D. Gatehouse,Andrew E. Arai,Matthias G. Friedrich,Stefan Neubauer,Jeanette Schulz-Menger,Jeanette Schulz-Menger,Erik B. Schelbert +12 more
TLDR
This document provides recommendations for clinical and research T1 and ECV measurement, based on published evidence when available and expert consensus when not, and addresses controversies in the field.Abstract:
Rapid innovations in cardiovascular magnetic resonance (CMR) now permit the routine acquisition of quantitative measures of myocardial and blood T1 which are key tissue characteristics. These capabilities introduce a new frontier in cardiology, enabling the practitioner/investigator to quantify biologically important myocardial properties that otherwise can be difficult to ascertain clinically. CMR may be able to track biologically important changes in the myocardium by: a) native T1 that reflects myocardial disease involving the myocyte and interstitium without use of gadolinium based contrast agents (GBCA), or b) the extracellular volume fraction (ECV)–a direct GBCA-based measurement of the size of the extracellular space, reflecting interstitial disease. The latter technique attempts to dichotomize the myocardium into its cellular and interstitial components with estimates expressed as volume fractions. This document provides recommendations for clinical and research T1 and ECV measurement, based on published evidence when available and expert consensus when not. We address site preparation, scan type, scan planning and acquisition, quality control, visualisation and analysis, technical development. We also address controversies in the field. While ECV and native T1 mapping appear destined to affect clinical decision making, they lack multi-centre application and face significant challenges, which demand a community-wide approach among stakeholders. At present, ECV and native T1 mapping appear sufficiently robust for many diseases; yet more research is required before a large-scale application for clinical decision-making can be recommended.read more
Citations
More filters
Journal ArticleDOI
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer,Gerasimos Filippatos,John J.V. McMurray,Victor Aboyans,Stephan Achenbach,Stefan Agewall,Nawwar Al-Attar,John Atherton,Johann Bauersachs,A. John Camm,Scipione Carerj,Claudio Ceconi,Antonio Coca,Perry M. Elliott,Çetin Erol,Justin A. Ezekowitz,Covadonga Fernández-Golfín,Donna Fitzsimons,Marco Guazzi,Maxime Guenoun,Gerd Hasenfuss,Gerhard Hindricks,Arno W. Hoes,Bernard Iung,Tiny Jaarsma,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Stavros Konstantinides,Mitja Lainscak,Patrizio Lancellotti,Gregory Y.H. Lip,Francesco Maisano,Christian Mueller,Mark C. Petrie,Massimo F Piepoli,Silvia G. Priori,Adam Torbicki,Hiroyuki Tsutsui,Dirk J. van Veldhuisen,Stephan Windecker,Clyde W. Yancy,José Luis Zamorano +62 more
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
Journal ArticleDOI
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer +20 more
TL;DR: ACCF/AHAIAI: angiotensin-converting enzyme inhibitor as discussed by the authors, angio-catabolizing enzyme inhibitor inhibitor inhibitor (ACS inhibitor) is a drug that is used to prevent atrial fibrillation.
Journal ArticleDOI
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer +20 more
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
Journal ArticleDOI
Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing
Jeanette Schulz-Menger,David A. Bluemke,Jens Bremerich,Scott D. Flamm,Mark A. Fogel,Matthias G. Friedrich,Raymond J. Kim,Florian von Knobelsdorff-Brenkenhoff,Christopher M. Kramer,Dudley J. Pennell,Sven Plein,Eike Nagel +11 more
TL;DR: This document addresses the need for agreement on specific standards for the interpretation and post-processing of CMR studies by providing consensus recommendations developed by the Task Force for Post Processing of the Society for Cardiovascular MR.
Journal ArticleDOI
Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations.
Vanessa M Ferreira,Jeanette Schulz-Menger,Godtfred Holmvang,Christopher M. Kramer,Iacopo Carbone,Udo Sechtem,Ingrid Kindermann,Matthias Gutberlet,Leslie T. Cooper,Peter Liu,Matthias G. Friedrich +10 more
TL;DR: This JACC Scientific Expert Panel provides consensus recommendations for an update of the cardiovascular magnetic resonance (CMR) diagnostic criteria for myocardial inflammation in patients with suspected acute or active myocardian inflammation (Lake Louise Criteria) that include options to use parametric mapping techniques.
References
More filters
Journal ArticleDOI
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.
Raymond J. Kim,Edwin Wu,Allen Rafael,Enn-Ling Chen,Michele Parker,Orlando P. Simonetti,Francis J. Klocke,Robert O. Bonow,Robert M. Judd +8 more
TL;DR: Reversible myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization and is strongly related to the degree of improvement in the global mean wall-motion score and the ejection fraction after Revascularization.
Journal ArticleDOI
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
Morteza Naghavi,Peter Libby,Erling Falk,S. Ward Casscells,S. Ward Casscells,Silvio H. Litovsky,Silvio H. Litovsky,John A. Rumberger,Juan J. Badimon,Christodoulos Stefanadis,Pedro R. Moreno,Gerard Pasterkamp,Zahi A. Fayad,Peter Stone,Sergio Waxman,Paolo Raggi,Mohammad Madjid,Mohammad Madjid,Alireza Zarrabi,Alireza Zarrabi,Allen P. Burke,Chun Yuan,Peter J. Fitzgerald,David S. Siscovick,Chris L. de Korte,Masanori Aikawa,K.E. Juhani Airaksinen,Gerd Assmann,Christoph R. Becker,James H. Chesebro,Andrew Farb,Zorina S. Galis,Christopher L. Jackson,Ik-Kyung Jang,Wolfgang Koenig,Robert A. Lodder,Keith L. March,Jasenka Demirovic,Mohamad Navab,Silvia G. Priori,Mark D. Rekhter,Raymond D. Bahr,Scott M. Grundy,Roxana Mehran,Antonio Colombo,Eric Boerwinkle,Christie M. Ballantyne,William Insull,Robert S. Schwartz,Robert A. Vogel,Patrick W. Serruys,Göran K. Hansson,David P. Faxon,Sanjay Kaul,Helmut Drexler,Philip Greenland,James E. Muller,Renu Virmani,Renu Virmani,Paul M. Ridker,Douglas P. Zipes,Prediman K. Shah,James T. Willerson,James T. Willerson +63 more
TL;DR: The term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future and a quantitative method for cumulative risk assessment of vulnerable patients needs to be developed.
Journal ArticleDOI
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Patrick M.M. Bossuyt,Johannes B. Reitsma,David E. Bruns,Constantine Gatsonis,Paul Glasziou,Les Irwig,Jeroen G. Lijmer,David Moher,Drummond Rennie,Henrica C.W. de Vet +9 more
TL;DR: If medical journals adopt the STARD checklist and flow diagram, the quality of reporting of studies of diagnostic accuracy should improve to the advantage of clinicians, researchers, reviewers, journals, and the public.
Journal ArticleDOI
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
TL;DR: How cell-intrinsic changes in important structural cells can perpetuate the fibrotic response by regulating the differentiation, recruitment, proliferation and activation of extracellular matrix–producing myofibroblasts is described.
Journal ArticleDOI
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.
Karl T. Weber,C G Brilla +1 more
TL;DR: It can be concluded that arterial hypertension together with elevated circulating aldosterone are associated with cardiac fibroblast involvement and the resultant heterogeneity in tissue structure and the stage is set to prevent pathological LVH resulting from myocardial fibrosis as well as to reverse it.